Roivant Sciences (ROIV) Expected to Announce Earnings on Thursday

Roivant Sciences (NASDAQ:ROIV - Get Free Report) is expected to announce its Q4 2025 earnings results before the market opens on Thursday, May 29th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $62.17 million for the quarter.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded down $0.11 during trading on Tuesday, hitting $10.76. 3,906,085 shares of the company's stock were exchanged, compared to its average volume of 5,572,613. The business has a 50-day simple moving average of $10.53 and a 200-day simple moving average of $11.04. Roivant Sciences has a 52-week low of $8.73 and a 52-week high of $13.06. The stock has a market capitalization of $7.68 billion, a price-to-earnings ratio of -71.73 and a beta of 1.23.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ROIV shares. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.

Insider Activity

In other news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the sale, the insider now owns 39,799,611 shares in the company, valued at $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eric Venker sold 315,522 shares of Roivant Sciences stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the completion of the sale, the chief operating officer now owns 959,457 shares in the company, valued at approximately $10,611,594.42. This trade represents a 24.75% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,223,959 shares of company stock worth $13,450,035 over the last 90 days. 7.90% of the stock is currently owned by company insiders.

Institutional Trading of Roivant Sciences

An institutional investor recently raised its position in Roivant Sciences stock. Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 15.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,433,386 shares of the company's stock after acquiring an additional 324,764 shares during the quarter. Goldman Sachs Group Inc. owned about 0.34% of Roivant Sciences worth $24,553,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.